Publications
Find coverage of the latest original articles on scleroderma, focusing on those with data on therapeutic interventions and those that have clinical impact.
Sponsored by Boehringer Ingelheim.
August 2025
Belumosudil in diffuse cutaneous systemic sclerosis: A randomized, double-blind, open-label extension, placebo-controlled, Phase 2 study
Rheumatology 2025;64:4299–4308 Doi: 10.1093/rheumatology/keaf062
Chung et al. showed that this prematurely terminated Phase 2 trial did not identify any trend toward belumosudil efficacy as the combined response index in systemic sclerosis score (CRISS) ≥0.60 responses were similar between belumosudil and placebo groups; but it was found to have acceptable safety and tolerability. Authors evaluated the efficacy, safety and PD of orally administered belumosudil (200mg QD or BID) in patients with dcSSc.